CEL-SCI (CVM) announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority for Multikine in Saudi Arabia. The application was submitted by a premier Saudi pharma company with which CEL-SCI has signed a memorandum of understanding for the commercialization of Multikine.The response time to the application is approximately 60 days. If granted, the designation would immediately make Multikine available for patient access and reimbursement in Saudi Arabia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVM: